newsfilter
← Latest News
Business Wire·

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

– LINZESS® (linaclotide) U.S. net sales of $315 million in Q3 2025, an increase of 40% year-over-year; EUTRx demand growth increased 12% year-over-year – – GAAP net income of $40 million and adjusted EBITDA of